{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:32:15Z","timestamp":1791102735856,"version":"4.1.0"},"reference-count":216,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.phrs.2010.02.010","type":"journal-article","created":{"date-parts":[[2010,2,27]],"date-time":"2010-02-27T09:40:50Z","timestamp":1267263650000},"page":"18-34","source":"Crossref","is-referenced-by-count":108,"title":["Histone deacetylases and epigenetic therapies of hematological malignancies"],"prefix":"10.1016","volume":"62","author":[{"given":"Ciro","family":"Mercurio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Minucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Giuseppe","family":"Pelicci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"April(4)","key":"10.1016\/j.phrs.2010.02.010_bib1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrg2005","article-title":"Cancer epigenomics: DNA methylomes and histone-modification maps","volume":"8","author":"Esteller","year":"2007","journal-title":"Nat Rev Genet"},{"issue":"August(5532)","key":"10.1016\/j.phrs.2010.02.010_bib2","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","article-title":"Translating the histone code","volume":"293","author":"Jenuwein","year":"2001","journal-title":"Science"},{"issue":"September(9)","key":"10.1016\/j.phrs.2010.02.010_bib3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.molmed.2007.07.003","article-title":"Chromatin remodeling and cancer. Part I. Covalent histone modifications","volume":"13","author":"Wang","year":"2007","journal-title":"Trends Mol Med"},{"issue":"January(1)","key":"10.1016\/j.phrs.2010.02.010_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.biocel.2008.08.028","article-title":"Marking time: the dynamic role of chromatin and covalent modification in transcription","volume":"41","author":"Reid","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.phrs.2010.02.010_bib5","doi-asserted-by":"crossref","unstructured":"The Rpd3\/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008;9(March(3)):206\u201318.","DOI":"10.1038\/nrm2346"},{"issue":"September(5)","key":"10.1016\/j.phrs.2010.02.010_bib6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cell.2009.06.049","article-title":"Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"issue":"June(12)","key":"10.1016\/j.phrs.2010.02.010_bib7","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","article-title":"Clinical studies of histone deacetylase inhibitors","volume":"15","author":"Prince","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"983","key":"10.1016\/j.phrs.2010.02.010_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1749-6632.2003.tb05964.x","article-title":"Histone deacetylases: unique players in shaping the epigenetic histone code","author":"Thiagalingam","year":"2003","journal-title":"Ann NY Acad Sci"},{"issue":"July(7255)","key":"10.1016\/j.phrs.2010.02.010_bib9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nature08197","article-title":"Recent progress in the biology and physiology of sirtuins","volume":"460","author":"Finkel","year":"2009","journal-title":"Nature"},{"issue":"May(1)","key":"10.1016\/j.phrs.2010.02.010_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20070140","article-title":"Sirtuins in mammals: insights into their biological function","volume":"404","author":"Michan","year":"2007","journal-title":"Biochem J"},{"issue":"June(6)","key":"10.1016\/j.phrs.2010.02.010_bib11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1517\/14728222.11.6.835","article-title":"The therapeutic uses of chromatin-modifying agents","volume":"11","author":"Mai","year":"2007","journal-title":"Expert Opin Ther Targets"},{"issue":"April(1)","key":"10.1016\/j.phrs.2010.02.010_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","article-title":"Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis","volume":"338","author":"Gregoretti","year":"2004","journal-title":"J Mol Biol"},{"issue":"May(5)","key":"10.1016\/j.phrs.2010.02.010_bib13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0168-9525(03)00073-8","article-title":"Class II histone deacetylases: versatile regulators","volume":"19","author":"Verdin","year":"2003","journal-title":"Trends Genet"},{"issue":"August(37)","key":"10.1016\/j.phrs.2010.02.010_bib14","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1038\/sj.onc.1210614","article-title":"HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination","volume":"26","author":"Boyault","year":"2007","journal-title":"Oncogene"},{"issue":"May(6887)","key":"10.1016\/j.phrs.2010.02.010_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature"},{"issue":"July(28)","key":"10.1016\/j.phrs.2010.02.010_bib16","doi-asserted-by":"crossref","first-page":"25748","DOI":"10.1074\/jbc.M111871200","article-title":"Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family","volume":"277","author":"Gao","year":"2002","journal-title":"J Biol Chem"},{"issue":"August(37)","key":"10.1016\/j.phrs.2010.02.010_bib17","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1038\/sj.onc.1210611","article-title":"The human Mi-2\/NuRD complex and gene regulation","volume":"26","author":"Denslow","year":"2007","journal-title":"Oncogene"},{"issue":"February(4)","key":"10.1016\/j.phrs.2010.02.010_bib18","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1073\/pnas.98.4.1454","article-title":"CoREST is an integral component of the CoREST-human histone deacetylase complex","volume":"98","author":"You","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"June(13)","key":"10.1016\/j.phrs.2010.02.010_bib19","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1073\/pnas.97.13.7202","article-title":"The histone deacetylase-3 complex contains nuclear receptor corepressors","volume":"97","author":"Wen","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"March(3)","key":"10.1016\/j.phrs.2010.02.010_bib20","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1097-2765(02)00468-9","article-title":"The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2","volume":"9","author":"Zhang","year":"2002","journal-title":"Mol Cell"},{"issue":"August(37)","key":"10.1016\/j.phrs.2010.02.010_bib21","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/sj.onc.1210612","article-title":"HDAC3: taking the SMRT-N-CoRrect road to repression","volume":"26","author":"Karagianni","year":"2007","journal-title":"Oncogene"},{"issue":"December(23)","key":"10.1016\/j.phrs.2010.02.010_bib22","doi-asserted-by":"crossref","first-page":"8035","DOI":"10.1128\/MCB.21.23.8035-8044.2001","article-title":"Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways","volume":"21","author":"Seigneurin-Berny","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"January(1)","key":"10.1016\/j.phrs.2010.02.010_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1097-2765(01)00429-4","article-title":"Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT\/N-CoR","volume":"9","author":"Fischle","year":"2002","journal-title":"Mol Cell"},{"issue":"September(38)","key":"10.1016\/j.phrs.2010.02.010_bib24","doi-asserted-by":"crossref","first-page":"35826","DOI":"10.1074\/jbc.M104935200","article-title":"Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo","volume":"276","author":"Fischle","year":"2001","journal-title":"J Biol Chem"},{"issue":"June(11)","key":"10.1016\/j.phrs.2010.02.010_bib25","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/emboj\/21.11.2672","article-title":"Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression","volume":"21","author":"Lagger","year":"2002","journal-title":"EMBO J"},{"issue":"July(14)","key":"10.1016\/j.phrs.2010.02.010_bib26","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1101\/gad.1563807","article-title":"Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility","volume":"21","author":"Montgomery","year":"2007","journal-title":"Genes Dev"},{"issue":"October(19)","key":"10.1016\/j.phrs.2010.02.010_bib27","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1158\/0008-5472.CAN-07-0312","article-title":"Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice","volume":"67","author":"Zimmermann","year":"2007","journal-title":"Cancer Res"},{"issue":"May(19)","key":"10.1016\/j.phrs.2010.02.010_bib28","doi-asserted-by":"crossref","first-page":"7876","DOI":"10.1073\/pnas.0902750106","article-title":"Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development","volume":"106","author":"Montgomery","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"March(5)","key":"10.1016\/j.phrs.2010.02.010_bib29","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1128\/MCB.01154-06","article-title":"Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally","volume":"28","author":"Zhang","year":"2008","journal-title":"Mol Cell Biol"},{"issue":"Novmber(4)","key":"10.1016\/j.phrs.2010.02.010_bib30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cell.2004.10.024","article-title":"Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis","volume":"119","author":"Vega","year":"2004","journal-title":"Cell"},{"issue":"October(19)","key":"10.1016\/j.phrs.2010.02.010_bib31","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.1128\/MCB.24.19.8467-8476.2004","article-title":"Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development","volume":"24","author":"Chang","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"July(2)","key":"10.1016\/j.phrs.2010.02.010_bib32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2006.05.040","article-title":"Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10","volume":"126","author":"Chang","year":"2006","journal-title":"Cell"},{"issue":"March","key":"10.1016\/j.phrs.2010.02.010_bib33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1749-6632.2003.tb05964.x","article-title":"Histone deacetylases: unique players in shaping the epigenetic histone code","volume":"983","author":"Thiagalingam","year":"2003","journal-title":"Ann NY Acad Sci"},{"issue":"June(6)","key":"10.1016\/j.phrs.2010.02.010_bib34","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1158\/1535-7163.MCT-08-0860","article-title":"Epigenetics in cancer: targeting chromatin modifications","volume":"8","author":"Ellis","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"April(4)","key":"10.1016\/j.phrs.2010.02.010_bib35","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/1535-7163.MCT-07-2284","article-title":"Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics","volume":"7","author":"Hadnagy","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"September(9)","key":"10.1016\/j.phrs.2010.02.010_bib36","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"January(1)","key":"10.1016\/j.phrs.2010.02.010_bib37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.phrs.2010.02.010_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","article-title":"Acetylation and deacetylation of non-histone proteins","volume":"December(363)","author":"Glozak","year":"2005","journal-title":"Gene"},{"issue":"July(27)","key":"10.1016\/j.phrs.2010.02.010_bib39","doi-asserted-by":"crossref","first-page":"20436","DOI":"10.1074\/jbc.M000202200","article-title":"Histone deacetylases specifically down-regulate p53-dependent gene activation","volume":"275","author":"Juan","year":"2000","journal-title":"J Biol Chem"},{"issue":"Novmber(6810)","key":"10.1016\/j.phrs.2010.02.010_bib40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/35042612","article-title":"Deacetylation of p53 modulates its effect on cell growth and apoptosis","volume":"408","author":"Luo","year":"2000","journal-title":"Nature"},{"issue":"May(5)","key":"10.1016\/j.phrs.2010.02.010_bib41","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor","volume":"18","author":"Kovacs","year":"2005","journal-title":"Mol Cell"},{"issue":"July(29)","key":"10.1016\/j.phrs.2010.02.010_bib42","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bali","year":"2005","journal-title":"J Biol Chem"},{"issue":"March(12)","key":"10.1016\/j.phrs.2010.02.010_bib43","doi-asserted-by":"crossref","first-page":"7436","DOI":"10.1074\/jbc.M808999200","article-title":"HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling","volume":"284","author":"Kekatpure","year":"2009","journal-title":"J Biol Chem"},{"issue":"February(4)","key":"10.1016\/j.phrs.2010.02.010_bib44","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/emboj\/19.4.662","article-title":"Regulation of E2F1 activity by acetylation","volume":"19","author":"Mart\u00ednez-Balb\u00e1s","year":"2000","journal-title":"EMBO J"},{"issue":"April(15)","key":"10.1016\/j.phrs.2010.02.010_bib45","doi-asserted-by":"crossref","first-page":"10887","DOI":"10.1074\/jbc.275.15.10887","article-title":"E2F family members are differentially regulated by reversible acetylation","volume":"275","author":"Marzio","year":"2000","journal-title":"J Biol Chem"},{"issue":"April(7)","key":"10.1016\/j.phrs.2010.02.010_bib46","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/sj.emboj.7600176","article-title":"Acetylation regulates the differentiation-specific functions of the retinoblastoma protein","volume":"23","author":"Nguyen","year":"2004","journal-title":"EMBO J"},{"issue":"December(4)","key":"10.1016\/j.phrs.2010.02.010_bib47","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/ng1018","article-title":"Acetylation inactivates the transcriptional repressor BCL6","volume":"32","author":"Bereshchenko","year":"2002","journal-title":"Nat Genet"},{"issue":"August(5942)","key":"10.1016\/j.phrs.2010.02.010_bib48","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"},{"issue":"August(4)","key":"10.1016\/j.phrs.2010.02.010_bib49","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.molcel.2006.06.026","article-title":"Substrate and functional diversity of lysine acetylation revealed by a proteomics survey","volume":"23","author":"Kim","year":"2006","journal-title":"Mol Cell"},{"issue":"January(1)","key":"10.1016\/j.phrs.2010.02.010_bib50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.biocel.2008.07.021","article-title":"Epigenomic profiling of cancer cells","volume":"41","author":"Gargiulo","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"issue":"July(2)","key":"10.1016\/j.phrs.2010.02.010_bib51","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.V94.2.417","article-title":"Chromatin remodeling and leukemia: new therapeutic paradigms","volume":"94","author":"Redner","year":"1999","journal-title":"Blood"},{"issue":"September(3)","key":"10.1016\/j.phrs.2010.02.010_bib52","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1046\/j.1365-2141.2002.03586.x","article-title":"Chromatin modification, leukaemia and implications for therapy","volume":"118","author":"Jones","year":"2002","journal-title":"Br J Haematol"},{"issue":"May(24)","key":"10.1016\/j.phrs.2010.02.010_bib53","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1038\/sj.onc.1204336","article-title":"Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?","volume":"20","author":"Minucci","year":"2001","journal-title":"Oncogene"},{"issue":"May(20)","key":"10.1016\/j.phrs.2010.02.010_bib54","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJM199105163242002","article-title":"Differentiation therapy of acute promyelocytic leukemia with all-trans-retinoic acid","volume":"324","author":"Warrell","year":"1991","journal-title":"N Engl J Med"},{"issue":"May(5)","key":"10.1016\/j.phrs.2010.02.010_bib55","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1097-2765(00)80322-6","article-title":"Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers","volume":"5","author":"Lin","year":"2000","journal-title":"Mol Cell"},{"issue":"May(5)","key":"10.1016\/j.phrs.2010.02.010_bib56","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1097-2765(00)80321-4","article-title":"Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation","volume":"5","author":"Minucci","year":"2000","journal-title":"Mol Cell"},{"issue":"April(2)","key":"10.1016\/j.phrs.2010.02.010_bib57","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1006\/scdb.1999.0303","article-title":"Retinoid receptors in health and disease: co-regulators and the chromatin connection","volume":"10","author":"Minucci","year":"1999","journal-title":"Semin Cell Dev Biol"},{"issue":"February(5557)","key":"10.1016\/j.phrs.2010.02.010_bib58","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.1065173","article-title":"Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor","volume":"295","author":"Di Croce","year":"2002","journal-title":"Science"},{"issue":"February(4)","key":"10.1016\/j.phrs.2010.02.010_bib59","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1128\/MCB.26.4.1288-1296.2006","article-title":"Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein","volume":"26","author":"Carbone","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"Novmber(9)","key":"10.1016\/j.phrs.2010.02.010_bib60","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1172\/JCI200111537","article-title":"Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia","volume":"108","author":"He","year":"2001","journal-title":"J Clin Invest"},{"issue":"May(24)","key":"10.1016\/j.phrs.2010.02.010_bib61","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1038\/sj.onc.1207727","article-title":"The 8;21 translocation in leukemogenesis","volume":"23","author":"Peterson","year":"2004","journal-title":"Oncogene"},{"issue":"September(18)","key":"10.1016\/j.phrs.2010.02.010_bib62","doi-asserted-by":"crossref","first-page":"10860","DOI":"10.1073\/pnas.95.18.10860","article-title":"ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR\/mSin3\/HDAC1 complex","volume":"95","author":"Wang","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"December(12)","key":"10.1016\/j.phrs.2010.02.010_bib63","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1128\/MCB.18.12.7176","article-title":"ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors","volume":"18","author":"Lutterbach","year":"1998","journal-title":"Mol Cell Biol"},{"issue":"December(12)","key":"10.1016\/j.phrs.2010.02.010_bib64","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.1128\/MCB.18.12.7185","article-title":"Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO","volume":"18","author":"Gelmetti","year":"1998","journal-title":"Mol Cell Biol"},{"issue":"April(4)","key":"10.1016\/j.phrs.2010.02.010_bib65","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.leukres.2003.08.016","article-title":"Domains involved in ETO and human N-CoR interaction and ETO transcription repression","volume":"28","author":"Wang","year":"2004","journal-title":"Leuk Res"},{"issue":"January(1)","key":"10.1016\/j.phrs.2010.02.010_bib66","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/MCB.21.1.156-163.2001","article-title":"Oligomerization of ETO is obligatory for corepressor interaction","volume":"21","author":"Zhang","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"March(12)","key":"10.1016\/j.phrs.2010.02.010_bib67","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.onc.1210820","article-title":"Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1\/ETO-positive cells","volume":"27","author":"Barbetti","year":"2008","journal-title":"Oncogene"},{"issue":"June(3)","key":"10.1016\/j.phrs.2010.02.010_bib68","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1124\/jpet.106.118406","article-title":"Targeting AML1\/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1\/ETO-positive acute myeloid leukemia cells","volume":"321","author":"Liu","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"June(12)","key":"10.1016\/j.phrs.2010.02.010_bib69","first-page":"2766","article-title":"Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells","volume":"59","author":"Wang","year":"1999","journal-title":"Cancer Res"},{"issue":"January(1)","key":"10.1016\/j.phrs.2010.02.010_bib70","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nm1161","article-title":"Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells","volume":"11","author":"Nebbioso","year":"2005","journal-title":"Nat Med"},{"issue":"January(2)","key":"10.1016\/j.phrs.2010.02.010_bib71","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1128\/MCB.23.2.607-619.2003","article-title":"The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain","volume":"23","author":"Durst","year":"2003","journal-title":"Mol Cell Biol"},{"issue":"May(24)","key":"10.1016\/j.phrs.2010.02.010_bib72","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1038\/sj.onc.1207748","article-title":"Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB\/PEBP2B-MHY11","volume":"23","author":"Shigesada","year":"2004","journal-title":"Oncogene"},{"issue":"June(6)","key":"10.1016\/j.phrs.2010.02.010_bib73","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.leukres.2007.11.038","article-title":"Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias","volume":"32","author":"Serrano","year":"2008","journal-title":"Leuk Res"},{"issue":"March(5)","key":"10.1016\/j.phrs.2010.02.010_bib74","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood-2003-07-2577","article-title":"Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia","volume":"103","author":"Ferrando","year":"2004","journal-title":"Blood"},{"issue":"June(6)","key":"10.1016\/j.phrs.2010.02.010_bib75","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ccr.2004.05.023","article-title":"TAL1\/SCL induces leukemia by inhibiting the transcriptional activity of E47\/HEB","volume":"5","author":"O\u2019Neil","year":"2004","journal-title":"Cancer Cell"},{"issue":"December(12)","key":"10.1016\/j.phrs.2010.02.010_bib76","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nri953","article-title":"Lymphoid malignancies: the dark side of B-cell differentiation","volume":"2","author":"Shaffer","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"October(20)","key":"10.1016\/j.phrs.2010.02.010_bib77","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1093\/nar\/26.20.4645","article-title":"The LAZ3(BCL-6) oncoprotein recruits a SMRT\/mSIN3A\/histone deacetylase containing complex to mediate transcriptional repression","volume":"26","author":"Dhordain","year":"1998","journal-title":"Nucleic Acids Res"},{"issue":"June(24)","key":"10.1016\/j.phrs.2010.02.010_bib78","doi-asserted-by":"crossref","first-page":"22045","DOI":"10.1074\/jbc.M201736200","article-title":"Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor","volume":"277","author":"Lemercier","year":"2002","journal-title":"J Biol Chem"},{"issue":"September(26)","key":"10.1016\/j.phrs.2010.02.010_bib79","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1200\/JCO.2005.05.014","article-title":"Targeting histones and proteasomes: new strategies for the treatment of lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J Clin Oncol"},{"issue":"October(10)","key":"10.1016\/j.phrs.2010.02.010_bib80","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.leu.2403910","article-title":"Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors","volume":"19","author":"Bradbury","year":"2005","journal-title":"Leukemia"},{"issue":"October(44)","key":"10.1016\/j.phrs.2010.02.010_bib81","doi-asserted-by":"crossref","first-page":"30673","DOI":"10.1074\/jbc.M109.042242","article-title":"Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors","volume":"284","author":"Wada","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2010.02.010_bib82","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Quesada AS, Maddipoti S, Kuang S, Tong W, Wierda WG. Analysis of class I and II histone deacetylase fails to identify a human leukemia specific expression profile. Blood (ASH annual meeting abstracts) 2007;110 [Abstract 2130].","DOI":"10.1182\/blood.V110.11.2130.2130"},{"issue":"May(6)","key":"10.1016\/j.phrs.2010.02.010_bib83","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2559.2009.03290.x","article-title":"Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas","volume":"54","author":"Marquard","year":"2009","journal-title":"Histopathology"},{"issue":"September(3)","key":"10.1016\/j.phrs.2010.02.010_bib84","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2559.2008.03109.x","article-title":"Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma","volume":"53","author":"Marquard","year":"2008","journal-title":"Histopathology"},{"issue":"December(12)","key":"10.1016\/j.phrs.2010.02.010_bib85","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1080\/10428190802527699","article-title":"Enhanced histone deacetylase enzyme activity in primary myelofibrosis","volume":"49","author":"Wang","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"September(3)","key":"10.1016\/j.phrs.2010.02.010_bib86","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/jpet.107.124461","article-title":"Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors","volume":"322","author":"Lee","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"April(8)","key":"10.1016\/j.phrs.2010.02.010_bib87","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","article-title":"Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells","volume":"101","author":"Nimmanapalli","year":"2003","journal-title":"Blood"},{"issue":"October(19)","key":"10.1016\/j.phrs.2010.02.010_bib88","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","article-title":"Cotreatment with Vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells","volume":"12","author":"Fiskus","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"June(3)","key":"10.1016\/j.phrs.2010.02.010_bib89","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/scd.2007.9994","article-title":"Depsipeptide (FK228) preferentially induces apoptosis in BCR\/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis","volume":"16","author":"Okabe","year":"2007","journal-title":"Stem Cells Dev"},{"issue":"July(1)","key":"10.1016\/j.phrs.2010.02.010_bib90","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-0609.2009.01242.x","article-title":"Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro","volume":"83","author":"Kircher","year":"2009","journal-title":"Eur J Haematol"},{"issue":"February(4)","key":"10.1016\/j.phrs.2010.02.010_bib91","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2004-09-3413","article-title":"Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3","volume":"105","author":"George","year":"2005","journal-title":"Blood"},{"issue":"January(1)","key":"10.1016\/j.phrs.2010.02.010_bib92","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nm1160","article-title":"Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway","volume":"11","author":"Insinga","year":"2005","journal-title":"Nat Med"},{"issue":"May(5)","key":"10.1016\/j.phrs.2010.02.010_bib93","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1096\/fj.06-8050com","article-title":"Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha","volume":"22","author":"Kr\u00e4mer","year":"2008","journal-title":"FASEB J"},{"issue":"August(8)","key":"10.1016\/j.phrs.2010.02.010_bib94","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/leu.2008.141","article-title":"Epigenetic plasticity of chromatin in embryonic and hematopoietic stem\/progenitor cells: therapeutic potential of cell reprogramming","volume":"22","author":"Zardo","year":"2008","journal-title":"Leukemia"},{"issue":"Novmber(9)","key":"10.1016\/j.phrs.2010.02.010_bib95","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.4049\/jimmunol.167.9.5160","article-title":"Loss of PU.1 expression following inhibition of histone deacetylases","volume":"167","author":"Laribee","year":"2001","journal-title":"J Immunol"},{"issue":"June(11)","key":"10.1016\/j.phrs.2010.02.010_bib96","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1182\/blood-2003-07-2431","article-title":"Modification of hematopoietic stem cell fate by 5aza 2\u2032deoxycytidine and trichostatin A","volume":"103","author":"Milhem","year":"2004","journal-title":"Blood"},{"issue":"February(4)","key":"10.1016\/j.phrs.2010.02.010_bib97","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1158\/0008-5472.CAN-04-3063","article-title":"Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells","volume":"65","author":"De Felice","year":"2005","journal-title":"Cancer Res"},{"issue":"April(7)","key":"10.1016\/j.phrs.2010.02.010_bib98","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/0008-5472.CAN-04-3011","article-title":"Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells","volume":"65","author":"Bug","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2010.02.010_bib99","doi-asserted-by":"crossref","unstructured":"G\u00fcl H, Marquez-Curtis LA, Jahroudi N, Larratt LM, Janowska-Wieczorek A, Valproic acid exerts differential effects on CXCR4 expression in leukemic cells. Leuk Res 2009(June) [Epub ahead of print].","DOI":"10.1016\/j.leukres.2009.05.014"},{"issue":"July\u2013August(6)","key":"10.1016\/j.phrs.2010.02.010_bib100","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1089\/scd.2008.0235","article-title":"Valproic acid increases CXCR4 expression in hematopoietic stem\/progenitor cells by chromatin remodeling","volume":"18","author":"G\u00fcl","year":"2009","journal-title":"Stem Cells Dev"},{"issue":"December(12)","key":"10.1016\/j.phrs.2010.02.010_bib101","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1158\/1535-7163.MCT-06-0418","article-title":"Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells","volume":"5","author":"Fiskus","year":"2006","journal-title":"Mol Cancer Ther"},{"issue":"September(13)","key":"10.1016\/j.phrs.2010.02.010_bib102","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood-2009-03-213496","article-title":"Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor Panobinostat against human AML cells","volume":"114","author":"Fiskus","year":"2009","journal-title":"Blood"},{"issue":"July(6)","key":"10.1016\/j.phrs.2010.02.010_bib103","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2174\/187152009788679976","article-title":"Histone deacetylase inhibitors: design, structure\u2013activity relationships and therapeutic implications for cancer","volume":"9","author":"Marson","year":"2009","journal-title":"Anticancer Agents Med Chem"},{"issue":"Novmber(32)","key":"10.1016\/j.phrs.2010.02.010_bib104","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J Clin Oncol"},{"issue":"July(4)","key":"10.1016\/j.phrs.2010.02.010_bib105","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: potential in cancer therapy","volume":"107","author":"Marks","year":"2009","journal-title":"J Cell Biochem"},{"issue":"April(8)","key":"10.1016\/j.phrs.2010.02.010_bib106","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0430973100","article-title":"Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation","volume":"100","author":"Haggarty","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Novmber(21)","key":"10.1016\/j.phrs.2010.02.010_bib107","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1021\/jm900555u","article-title":"Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy","volume":"52","author":"Ontoria","year":"2009","journal-title":"J Med Chem"},{"issue":"May(9)","key":"10.1016\/j.phrs.2010.02.010_bib108","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1021\/jm049002a","article-title":"Class II (IIA)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides","volume":"48","author":"Mai","year":"2005","journal-title":"J Med Chem"},{"issue":"August(2)","key":"10.1016\/j.phrs.2010.02.010_bib109","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.canlet.2009.02.028","article-title":"HDACi\u2014targets beyond chromatin","volume":"280","author":"Buchwald","year":"2009","journal-title":"Cancer Lett"},{"issue":"December(12)","key":"10.1016\/j.phrs.2010.02.010_bib110","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1517\/13543784.14.12.1497","article-title":"Histone deacetylase inhibitors: discovery and development as anticancer agents","volume":"14","author":"Marks","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"issue":"January(3)","key":"10.1016\/j.phrs.2010.02.010_bib111","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1073\/pnas.0408732102","article-title":"Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors","volume":"102","author":"Ungerstedt","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"August(15)","key":"10.1016\/j.phrs.2010.02.010_bib112","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"December(4)","key":"10.1016\/j.phrs.2010.02.010_bib113","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/1568009023333818","article-title":"Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress","volume":"2","author":"Gabrielli","year":"2002","journal-title":"Curr Cancer Drug Targets"},{"issue":"August(18)","key":"10.1016\/j.phrs.2010.02.010_bib114","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1073\/pnas.180316197","article-title":"Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation","volume":"97","author":"Richon","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Novmber(3)","key":"10.1016\/j.phrs.2010.02.010_bib115","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0014-5793(03)01186-4","article-title":"p15(INK4b) in HDAC inhibitor-induced growth arrest","volume":"554","author":"Hitomi","year":"2003","journal-title":"FEBS Lett"},{"issue":"February(2)","key":"10.1016\/j.phrs.2010.02.010_bib116","first-page":"151","article-title":"Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines","volume":"2","author":"Staver","year":"2003","journal-title":"Mol Cancer Ther"},{"issue":"June(6)","key":"10.1016\/j.phrs.2010.02.010_bib117","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1091\/mbc.11.6.2069","article-title":"Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells","volume":"11","author":"Qiu","year":"2000","journal-title":"Mol Biol Cell"},{"issue":"June(12)","key":"10.1016\/j.phrs.2010.02.010_bib118","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1158\/1078-0432.CCR-08-2787","article-title":"Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications","volume":"15","author":"Schrump","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"August(37)","key":"10.1016\/j.phrs.2010.02.010_bib119","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"issue":"May(2)","key":"10.1016\/j.phrs.2010.02.010_bib120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/jcp.20235","article-title":"Involvement of the tumor necrosis factor (TNF)\/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor Depsipeptide (FK228)","volume":"203","author":"Sutheesophon","year":"2005","journal-title":"J Cell Physiol"},{"issue":"April(4)","key":"10.1016\/j.phrs.2010.02.010_bib121","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/1535-7163.425.3.4","article-title":"The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells","volume":"3","author":"Zhang","year":"2004","journal-title":"Mol Cancer Ther"},{"issue":"September(19)","key":"10.1016\/j.phrs.2010.02.010_bib122","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1073\/pnas.191208598","article-title":"The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species","volume":"98","author":"Ruefli","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"December(12)","key":"10.1016\/j.phrs.2010.02.010_bib123","first-page":"1273","article-title":"Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells","volume":"2","author":"Rosato","year":"2003","journal-title":"Mol Cancer Ther"},{"issue":"December(52)","key":"10.1016\/j.phrs.2010.02.010_bib124","doi-asserted-by":"crossref","first-page":"18030","DOI":"10.1073\/pnas.0408345102","article-title":"Apoptotic and autophagic cell death induced by histone deacetylase inhibitors","volume":"101","author":"Shao","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"September(17)","key":"10.1016\/j.phrs.2010.02.010_bib125","doi-asserted-by":"crossref","first-page":"7832","DOI":"10.1158\/0008-5472.CAN-04-4608","article-title":"Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects","volume":"65","author":"Xu","year":"2005","journal-title":"Cancer Res"},{"issue":"September(9)","key":"10.1016\/j.phrs.2010.02.010_bib126","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1091\/mbc.e03-01-0860","article-title":"Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects","volume":"14","author":"Cimini","year":"2003","journal-title":"Mol Biol Cell"},{"issue":"June(6)","key":"10.1016\/j.phrs.2010.02.010_bib127","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/sj.embor.7400441","article-title":"The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?","volume":"6","author":"Taddei","year":"2005","journal-title":"EMBO Rep"},{"issue":"March(2)","key":"10.1016\/j.phrs.2010.02.010_bib128","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/156800908783769355","article-title":"Modulation of TRAIL-induced apoptosis by HDAC inhibitors","volume":"8","author":"Fulda","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"issue":"Novmber(45)","key":"10.1016\/j.phrs.2010.02.010_bib129","doi-asserted-by":"crossref","first-page":"17777","DOI":"10.1073\/pnas.0702518104","article-title":"A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors","volume":"104","author":"Epping","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"January(1)","key":"10.1016\/j.phrs.2010.02.010_bib130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccr.2008.12.001","article-title":"Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis","volume":"15","author":"Fotheringham","year":"2009","journal-title":"Cancer Cell"},{"issue":"August(2)","key":"10.1016\/j.phrs.2010.02.010_bib131","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.canlet.2008.11.012","article-title":"Targeting tumor angiogenesis with histone deacetylase inhibitors","volume":"280","author":"Ellis","year":"2009","journal-title":"Cancer Lett"},{"issue":"March(4)","key":"10.1016\/j.phrs.2010.02.010_bib132","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.bbrc.2004.01.149","article-title":"Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials","volume":"315","author":"Kim","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"December(12)","key":"10.1016\/j.phrs.2010.02.010_bib133","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood.V96.12.3847","article-title":"Up-regulation of costimulatory\/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells","volume":"96","author":"Maeda","year":"2000","journal-title":"Blood"},{"issue":"March(11)","key":"10.1016\/j.phrs.2010.02.010_bib134","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1073\/pnas.0400380101","article-title":"Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect","volume":"101","author":"Reddy","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"December(24)","key":"10.1016\/j.phrs.2010.02.010_bib135","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1158\/1078-0432.CCR-07-2114","article-title":"Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications","volume":"13","author":"Fantin","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"May(19)","key":"10.1016\/j.phrs.2010.02.010_bib136","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1073\/pnas.0702294104","article-title":"Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma","volume":"104","author":"Lindemann","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"May(5)","key":"10.1016\/j.phrs.2010.02.010_bib137","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1158\/1535-7163.MCT-07-2256","article-title":"Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor Romidepsin","volume":"7","author":"Newbold","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"May(10)","key":"10.1016\/j.phrs.2010.02.010_bib138","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1158\/0008-5472.CAN-07-6091","article-title":"Constitutive activation of signal transducers and activators of transcription predicts Vorinostat resistance in cutaneous T-cell lymphoma","volume":"68","author":"Fantin","year":"2008","journal-title":"Cancer Res"},{"issue":"October(42)","key":"10.1016\/j.phrs.2010.02.010_bib139","doi-asserted-by":"crossref","first-page":"15540","DOI":"10.1073\/pnas.0607518103","article-title":"Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor","volume":"103","author":"Xu","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Novmber(11)","key":"10.1016\/j.phrs.2010.02.010_bib140","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1158\/1535-7163.MCT-06-0298","article-title":"Ornithine decarboxylase activity in tumor cell lines correlates with sensitivity to cell death induced by histone deacetylase inhibitors","volume":"5","author":"Saunders","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.phrs.2010.02.010_bib141","doi-asserted-by":"crossref","unstructured":"Xiao JJ, Huang Y, Dai Z, Sad\u00e9e W, Chen J, Liu S, et al. Chemoresistance to Depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther 2005;314(July(1)):467\u201375.","DOI":"10.1124\/jpet.105.083956"},{"issue":"June(11)","key":"10.1016\/j.phrs.2010.02.010_bib142","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-08-2048","article-title":"Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes","volume":"15","author":"Hauswald","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"March(3)","key":"10.1016\/j.phrs.2010.02.010_bib143","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/ncponc0106","article-title":"Drug insight: histone deacetylase inhibitors\u2014development of the new targeted anticancer agent suberoylanilide hydroxamic acid","volume":"2","author":"Kelly","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"issue":"February(9)","key":"10.1016\/j.phrs.2010.02.010_bib144","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"issue":"January(1)","key":"10.1016\/j.phrs.2010.02.010_bib145","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies","volume":"24","author":"O\u2019Connor","year":"2006","journal-title":"J Clin Oncol"},{"issue":"May(5)","key":"10.1016\/j.phrs.2010.02.010_bib146","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/annonc\/mdn031","article-title":"Phase II trial of oral Vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma","volume":"19","author":"Crump","year":"2008","journal-title":"Ann Oncol"},{"issue":"October(10)","key":"10.1016\/j.phrs.2010.02.010_bib147","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2010.02.010_bib148","doi-asserted-by":"crossref","unstructured":"Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007;16(July(7)):1111\u201320; 12(October(10)):1247\u201352.","DOI":"10.1517\/13543784.16.7.1111"},{"issue":"July(21)","key":"10.1016\/j.phrs.2010.02.010_bib149","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIB multicenter trial of Vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"April(8)","key":"10.1016\/j.phrs.2010.02.010_bib150","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-06-2672","article-title":"Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma","volume":"13","author":"Mann","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"January(1)","key":"10.1016\/j.phrs.2010.02.010_bib151","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral Vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"issue":"May(10)","key":"10.1016\/j.phrs.2010.02.010_bib152","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1158\/0008-5472.CAN-07-6091","article-title":"Constitutive activation of signal transducers and activators of transcription predicts Vorinostat resistance in cutaneous T-cell lymphoma","volume":"68","author":"Fantin","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2010.02.010_bib153","doi-asserted-by":"crossref","unstructured":"Kirschbaum MH, Goldman BH, Zain JM, Cook JR, Rimsza LM, Forman SJ, et al. Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory Hodgkin lymphoma: SWOG 0517. Blood (ASH annual meeting abstracts) 2007;110:2574.","DOI":"10.1182\/blood.V110.11.2574.2574"},{"key":"10.1016\/j.phrs.2010.02.010_bib154","unstructured":"Kirschbaum MH, Zain JM, Popplewell L, Pullarkat V, Nademanee AP, Delioukina ML, et al. A phase 2 study of Vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non Hodgkin lymphoma. A California Cancer Consortium Study. Blood (ASH annual meeting abstracts) 2007;110:2568."},{"issue":"February(3)","key":"10.1016\/j.phrs.2010.02.010_bib155","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor Vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"issue":"March(3)","key":"10.1016\/j.phrs.2010.02.010_bib156","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral Vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"Richardson","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"January(2)","key":"10.1016\/j.phrs.2010.02.010_bib157","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/BJ20070779","article-title":"Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors","volume":"409","author":"Khan","year":"2008","journal-title":"Biochem J"},{"issue":"April(4)","key":"10.1016\/j.phrs.2010.02.010_bib158","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1517\/13543780902852560","article-title":"Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor","volume":"18","author":"Gimsing","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"September(3)","key":"10.1016\/j.phrs.2010.02.010_bib159","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1600-0609.2008.01102.x","article-title":"A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia","volume":"81","author":"Gimsing","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.phrs.2010.02.010_bib160","doi-asserted-by":"crossref","unstructured":"Zain JM, Foss F, Kelly WK, DeBono J, Petrylak D, Narwal A, et al. Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma J Clin Oncol (ASCO annual meeting 2009) 2009;27:15s(Suppl) [Abstract 8580].","DOI":"10.1200\/jco.2009.27.15_suppl.8580"},{"key":"10.1016\/j.phrs.2010.02.010_bib161","doi-asserted-by":"crossref","unstructured":"Pohlman B, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, et al. Final results of a phase II trial of Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Blood (ASH annual meeting abstract) 2009:920 [Abstract].","DOI":"10.1182\/blood.V114.22.920.920"},{"issue":"June(5)","key":"10.1016\/j.phrs.2010.02.010_bib162","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2217\/fon.09.36","article-title":"Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors","volume":"5","author":"Prince","year":"2009","journal-title":"Future Oncol"},{"issue":"August(2)","key":"10.1016\/j.phrs.2010.02.010_bib163","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor Panobinostat (LBH589): successes and challenges","volume":"280","author":"Atadja","year":"2009","journal-title":"Cancer Lett"},{"issue":"August(15)","key":"10.1016\/j.phrs.2010.02.010_bib164","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1158\/1078-0432.CCR-06-0511","article-title":"A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies","volume":"12","author":"Giles","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2010.02.010_bib165","doi-asserted-by":"crossref","unstructured":"Sharma S, Vogelzang NJ, Beck J, Patnaik A, Mita M, Dugan M, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589, a novel deacetylase (DAC) inhibitor given intravenously on a new once weekly schedule. J Clin Oncol 2007;25:18S(June(Suppl)) [14019].","DOI":"10.1016\/S1359-6349(07)70501-3"},{"key":"10.1016\/j.phrs.2010.02.010_bib166","doi-asserted-by":"crossref","unstructured":"Prince HM, George DJ, Patnaik A, Mita N, Dugan M, Butterfoss D, et al. Phase study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and Non-Hodgkin's lymphoma J Clin Oncol 2007;25 [Abstract 3500].","DOI":"10.1200\/jco.2007.25.18_suppl.3500"},{"issue":"July(14)","key":"10.1016\/j.phrs.2010.02.010_bib167","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/1078-0432.CCR-07-4262","article-title":"Histone deacetylase inhibitor Panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma","volume":"14","author":"Ellis","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2010.02.010_bib168","doi-asserted-by":"crossref","unstructured":"Duvic FV, Vanaclocha F, Bernengo MG, Okada C, Breneman D, Zinzani PL, et al. Phase II trial of oral Panobinostat (LBH589) in patients with refractory cutaneous T-cell. J Clin Oncol 2008;26(May(Suppl)) [Abstract 8555 1005].","DOI":"10.1200\/jco.2008.26.15_suppl.8555"},{"issue":"October(1)","key":"10.1016\/j.phrs.2010.02.010_bib169","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2009.07837.x","article-title":"Preliminary evidence of disease response to the pan deacetylase inhibitor Panobinostat (LBH589) in refractory Hodgkin lymphoma","volume":"147","author":"Dickinson","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.phrs.2010.02.010_bib170","doi-asserted-by":"crossref","unstructured":"Younes A, Ong T-C, Ribrag V, Engert A, Ben-Yehuda D, McCabe R. Efficacy of Panobinostat in phase II study in patients with relapsed\/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant. Blood (ASH annual meeting) 2009;(December) [Abstract: 923].","DOI":"10.1182\/blood.V114.22.923.923"},{"key":"10.1016\/j.phrs.2010.02.010_bib171","doi-asserted-by":"crossref","unstructured":"Ottmann OG, Spencer A, Miles Prince H, Bhalla KN, Fischer T, Liu A, et al., Phase IA\/II study of oral Panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. Blood (ASH annual meeting abstracts) 2008;112 [Abstract 958].","DOI":"10.1182\/blood.V112.11.958.958"},{"key":"10.1016\/j.phrs.2010.02.010_bib172","doi-asserted-by":"crossref","unstructured":"Wolf JL, Siegel D, Matous J, Lonial S, Goldschmidt H, Schmitt S, et al., A phase II study of oral Panobinostat (LBH589) in adult patients with advanced refractory multiple myeloma. Blood (ASH annual meeting abstracts) 2008;112 [Abstract 4254].","DOI":"10.1182\/blood.V112.11.2774.2774"},{"key":"10.1016\/j.phrs.2010.02.010_bib173","doi-asserted-by":"crossref","unstructured":"Zaritskey A, Alimena G, Konopka L, Shamsazar J, Bourquelot PM, Jallaludain M, et al. A phase II study of oral Panobinostat (LBH589) for chronic phase chronic myeloid leukemia (CML) with resistance to \u22652 BCR-ABL tyrosine kinase inhibitors. Blood (ASH annual meeting abstracts) 2008;112(November):4254.","DOI":"10.1182\/blood.V112.11.4254.4254"},{"issue":"January\u2013December(1\u201312)","key":"10.1016\/j.phrs.2010.02.010_bib174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2119\/2006-00005.Dinarello","article-title":"The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo","volume":"11","author":"Leoni","year":"2005","journal-title":"Mol Med"},{"issue":"February(2)","key":"10.1016\/j.phrs.2010.02.010_bib175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00277-009-0793-8","article-title":"A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma","volume":"89","author":"Galli","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.phrs.2010.02.010_bib176","doi-asserted-by":"crossref","unstructured":"Viviani S, Bonfante V, Fasola C, Valagussa P, Gianni AM. Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed\/refractory Hodgkin's lymphoma patients. J Clin Oncol 2008;26(May(Suppl)) [Abstract 8532].","DOI":"10.1200\/jco.2008.26.15_suppl.8532"},{"key":"10.1016\/j.phrs.2010.02.010_bib177","doi-asserted-by":"crossref","unstructured":"Rambaldi A, Dellacasa CM, Salmoiraghi S, Spinelli O, Ferrari ML, Gattoni E, et al. A phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms. Blood (ASH annual meeting abstracts) 2008;112 [Abstract 100].","DOI":"10.1182\/blood.V112.11.100.100"},{"issue":"June(11)","key":"10.1016\/j.phrs.2010.02.010_bib178","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1158\/1078-0432.CCR-07-4427","article-title":"Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay","volume":"14","author":"Bonfils","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"June(6)","key":"10.1016\/j.phrs.2010.02.010_bib179","first-page":"485","article-title":"Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer","volume":"8","author":"Kell","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"issue":"April(4)","key":"10.1016\/j.phrs.2010.02.010_bib180","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1535-7163.MCT-07-2026","article-title":"MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo","volume":"7","author":"Fournel","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.phrs.2010.02.010_bib181","doi-asserted-by":"crossref","unstructured":"Stimson L, Wood V, Khan O, Fotheringham S, La Thangue NB. HDAC inhibitorbased therapies and haematological malignancy. Ann Oncol 2009;20(August(8)):1293\u2013302.","DOI":"10.1093\/annonc\/mdn792"},{"key":"10.1016\/j.phrs.2010.02.010_bib182","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008;112(August(4)):981\u20139.","DOI":"10.1182\/blood-2007-10-115873"},{"key":"10.1016\/j.phrs.2010.02.010_bib183","doi-asserted-by":"crossref","unstructured":"Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008;26:1940\u20137.","DOI":"10.1200\/JCO.2007.14.5730"},{"key":"10.1016\/j.phrs.2010.02.010_bib184","doi-asserted-by":"crossref","unstructured":"Crump M, Andreadis C, Assouline S, Rizzieri D, Wedgwood A, McLaughlin P, et al. Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study. J Clin Oncol 2008;26(May(Suppl)) [Abstract 8528].","DOI":"10.1200\/jco.2008.26.15_suppl.8528"},{"key":"10.1016\/j.phrs.2010.02.010_bib185","doi-asserted-by":"crossref","unstructured":"Bociek RG, Kuruvilla J, Pro B, Wedgwood A, Li Z, Drouin M, et al. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed\/refractory classical Hodgkin lymphoma (HL). J Clin Oncol 2008;26(May(Suppl)) [Abstract 8507].","DOI":"10.1200\/jco.2008.26.15_suppl.8507"},{"issue":"7\u20138","key":"10.1016\/j.phrs.2010.02.010_bib186","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.biocel.2007.02.009","article-title":"MS-275, a potent orally available inhibitor of histone deacetylases\u2014the development of an anticancer agent","volume":"39","author":"Hess-Stumpp","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"issue":"June(17)","key":"10.1016\/j.phrs.2010.02.010_bib187","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2005.02.188","article-title":"Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma","volume":"23","author":"Ryan","year":"2005","journal-title":"J Clin Oncol"},{"issue":"April(7)","key":"10.1016\/j.phrs.2010.02.010_bib188","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1182\/blood-2006-05-021873","article-title":"Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias","volume":"109","author":"Gojo","year":"2007","journal-title":"Blood"},{"issue":"September(18 Pt 1)","key":"10.1016\/j.phrs.2010.02.010_bib189","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1158\/1078-0432.CCR-07-0791","article-title":"Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies","volume":"13","author":"Kummar","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"May(7)","key":"10.1016\/j.phrs.2010.02.010_bib190","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ejca.2009.03.001","article-title":"Epigenetic therapies in haematological malignancies: searching for true targets","volume":"45","author":"Altucci","year":"2009","journal-title":"Eur J Cancer"},{"issue":"Novmber(5)","key":"10.1016\/j.phrs.2010.02.010_bib191","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00280-005-0182-5","article-title":"FK228 (Depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities","volume":"58","author":"Konstantinopoulos","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"February(3)","key":"10.1016\/j.phrs.2010.02.010_bib192","first-page":"959","article-title":"A phase 1 and pharmacodynamic study of Depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"issue":"February(3)","key":"10.1016\/j.phrs.2010.02.010_bib193","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/1078-0432.CCR-07-0318","article-title":"Tolerability, pharmacodynamics, and pharmacokinetics studies of Depsipeptide (Romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes","volume":"14","author":"Klimek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2010.02.010_bib194","unstructured":"http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2009\/ucm189629.htm."},{"key":"10.1016\/j.phrs.2010.02.010_bib195","doi-asserted-by":"crossref","unstructured":"Kim Y, Whittaker S, Demierre MF, Rook AH, Lerner A, Duvic M, et al. Clinically significant responses achieved with Romidepsin in treatment-refractory cutaneous T-cell lymphoma: final results from a phase 2B, International, Multicenter, Registration Study. Blood (ASH annual meeting abstracts) 2008;112 [Abstract 263].","DOI":"10.1182\/blood.V112.11.263.263"},{"key":"10.1016\/j.phrs.2010.02.010_bib196","doi-asserted-by":"crossref","unstructured":"Bates S, Piekarz R, Wright J, Frye R, Figg Sr. WD, Allen AL, et al. Final clinical results of a phase 2 NCI multicenter study of Romidepsin in recurrent cutaneous T-cell lymphoma (molecular analyses included). Blood (ASH annual meeting abstracts) 2008;112 [Abstract 1568].","DOI":"10.1182\/blood.V112.11.1568.1568"},{"issue":"January(2)","key":"10.1016\/j.phrs.2010.02.010_bib197","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2141.2009.07954.x","article-title":"Laboratory correlates for a phase II trial of Romidepsin in cutaneous and peripheral T-cell lymphoma","volume":"148","author":"Bates","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.phrs.2010.02.010_bib198","doi-asserted-by":"crossref","unstructured":"Piekarz R, Wright J, Frye R, Allen SL, Craig M, Geskin L. Results of a phase 2 NCI multicenter study of Romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). Blood (ASH annual meeting abstracts) 2008;112(November):1567.","DOI":"10.1182\/blood.V112.11.1567.1567"},{"key":"10.1016\/j.phrs.2010.02.010_bib199","doi-asserted-by":"crossref","unstructured":"Niesvizky R, Ely S, DiLiberto M, Cho HJ, Gelbshtein UY, Jayabalan DS, et al. Multicenter phase II trial of the histone deacetylase inhibitor Depsipeptide (FK228) for the treatment of relapsed or refractory multiple myeloma (MM). Blood (ASH annual meeting abstracts) 2005;106(November):2574.","DOI":"10.1182\/blood.V106.11.2574.2574"},{"issue":"Novmber(21)","key":"10.1016\/j.phrs.2010.02.010_bib200","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1158\/1078-0432.CCR-08-1007","article-title":"Histone deacetylase inhibitor Romidepsin has differential activity in core binding factor acute myeloid leukemia","volume":"14","author":"Odenike","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"June(12)","key":"10.1016\/j.phrs.2010.02.010_bib201","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","article-title":"Cardiac studies in patients treated with Depsipeptide, FK228, in a phase II trial for T-cell lymphoma","volume":"12","author":"Piekarz","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2010.02.010_bib202","unstructured":"www.clinical trial gov."},{"issue":"June(12)","key":"10.1016\/j.phrs.2010.02.010_bib203","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1158\/1078-0432.CCR-08-2786","article-title":"Rational combinations using HDAC inhibitors","volume":"15","author":"Bots","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2010.02.010_bib204","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1158\/0008-5472.CAN-07-5989","article-title":"Role oft he aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation","volume":"68","author":"Rodriguez-Gonzalez","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2010.02.010_bib205","doi-asserted-by":"crossref","unstructured":"Simms-Waldrip T, Rodriguez-Gonzalez A, Lin T, Ikeda AK, Fu C, Sakamoto KM. The aggresome pathway as a target for therapy in hematologic malignancies. Mol Genet Metab 2008;94(July(3)):283\u20136.","DOI":"10.1016\/j.ymgme.2008.03.012"},{"issue":"Novmber(10)","key":"10.1016\/j.phrs.2010.02.010_bib206","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2006-04-016055","article-title":"Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells","volume":"108","author":"Catley","year":"2006","journal-title":"Blood"},{"issue":"August(16)","key":"10.1016\/j.phrs.2010.02.010_bib207","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-08-2850","article-title":"Phase I study of Vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma","volume":"15","author":"Badros","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2010.02.010_bib208","doi-asserted-by":"crossref","unstructured":"Siegel D, Sezer O, San Miguel JF, Mateos M-V, Prosser I, Cavo M, et al. Phase IB, multicenter, open-label, dose-escalation study of oral Panobinostat (LBH589) and I.V. bortezomib in patients with relapsed multiple myeloma. Blood (ASH annual meeting abstracts) 2008;112(November):2781.","DOI":"10.1182\/blood.V112.11.2781.2781"},{"key":"10.1016\/j.phrs.2010.02.010_bib209","doi-asserted-by":"crossref","unstructured":"Harrison SJ, Quach H, Yuen K, Strayer A, Copeman MC, Phil D, et al. High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor Romidepsin in patients with relapsed or refractory multiple myeloma in a phase I\/II clinical trial. Blood (ASH annual meeting abstracts) 2008;112(November):3698.","DOI":"10.1182\/blood.V112.11.3698.3698"},{"issue":"May(5)","key":"10.1016\/j.phrs.2010.02.010_bib210","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1517\/13543784.16.5.659","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"16","author":"Rasheed","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.phrs.2010.02.010_bib211","doi-asserted-by":"crossref","unstructured":"Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 2006;20(January(1)):1\u201313.","DOI":"10.1016\/j.blre.2005.01.006"},{"key":"10.1016\/j.phrs.2010.02.010_bib212","doi-asserted-by":"crossref","unstructured":"Cameron EE, Bachman KE, My\u00f6h\u00e4nen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21(January(1)):103\u20137.","DOI":"10.1038\/5047"},{"key":"10.1016\/j.phrs.2010.02.010_bib213","doi-asserted-by":"crossref","unstructured":"Silverman LR, Verma A, Odchimar-Reissig R, Cozza A, Najfeld V, Litch JD, et al. Phase I\/II study of Vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome(MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium [abstract]. J Clin Oncol (meeting abstracts) 2008;26(Suppl 15):7000.","DOI":"10.1200\/jco.2008.26.15_suppl.7000"},{"key":"10.1016\/j.phrs.2010.02.010_bib214","doi-asserted-by":"crossref","unstructured":"Odenike O, Green M, Larson RA, Rich ES, Ott J, Ratain MJ, et al. Phase I study of belinostat (PXD101) plus azacitidine(AZC) in patients with advanced myeloid neoplasms. J Clin Oncol (meeting abstracts) 2008;26(Suppl 15):7057.","DOI":"10.1200\/jco.2008.26.15_suppl.7057"},{"key":"10.1016\/j.phrs.2010.02.010_bib215","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Tambaro FP, Bekele BN, Jabbour E, Ravandi F, Yang H, et al. Phase II study of Vorinostat in combination with Idarubicin (Ida) and Cytarabine (ara-C) as front line therapy in acute myelogenous leukemia (AML) or higher risk myelodysplastic syndrome (MDS). Blood (ASH annual meeting abstracts) 2008;112(November):1055.","DOI":"10.1182\/blood.V114.22.1055.1055"},{"issue":"February(3)","key":"10.1016\/j.phrs.2010.02.010_bib216","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/0008-5472.CAN-08-2216","article-title":"Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer","volume":"69","author":"Welsbie","year":"2009","journal-title":"Cancer Res"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661810000629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661810000629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T17:16:08Z","timestamp":1685466968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661810000629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":216,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S1043661810000629"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2010.02.010","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}